About Pherin Pharmaceuticals
Pherin Pharmaceuticals is a Healthcare company based in Los Altos (United States) founded in 1991, and was acquired by VistaGen in December 2022. Intranasal pherines for anxiety and depression treatments are developed. Its chief executive, as recorded, is Kevin McCarthy. The company was acqui-hired. Its focus areas include Life Sciences, Neurology, Drugs and Psychiatric. Its competitors include Alto Neuroscience, Supernus Pharmaceuticals and Neurovance; 2 of its 3 listed competitors have raised funding.
Company details
Pherin Pharmaceuticals is a clinical stage specialty drug development company. It develops intranasal spray delivery in ultra low (nanogram) dose. It works exclusively with a set of proprietary compounds called pherines for the acute and PRN treatment of neuropsychiatric and neuroendocrine conditions. Pherines act by binding to nasal receptors and initiating neural impulses that are transmitted by specific neural circuits that directly and rapidly affect brain function. Their pipeline consists of four lead compounds: Aloradine IN for acute treatment of Social Anxiety Disorder (currently in Phase III); PH10 nasal spray for acute treatment of Depression (currently in Phase II); Salubrin HF NS, for acute management of Menopausal Hot Flashes and other symptoms of menopause (also in Phase II); and PH15 nasal spray for Cognitive Improvement (in Phase I trials).
- Headquarters Los Altos, United States
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website pherin.com
- Acquired by VistaGen (Dec 2022)
Funding Insights of Pherin Pharmaceuticals
- Total Rounds 1
- Last Round Unspecified β $1.5M
- First Round $1.5M
(Jul 1999)
- Investors Count 1
All 1 funding rounds of Pherin Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 1999 | $1.5M | Unspecified | β | β |
2 investors in total: 2 institutional.
Investors in Pherin Pharmaceuticals
Pherin Pharmaceuticals has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include VistaGen and Johnson & Johnson Innovation β JJDC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
Small molecules are developed for CNS disease treatments. | 1998 | vistagen.com | Francisco, United States |
Investor details for Pherin Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pherin Pharmaceuticals
1 people are tracked at Pherin Pharmaceuticals (1 in leadership).
| Name | Role | Group |
|---|---|---|
Kevin McCarthy | CEO | Leadership |
Complete people profiles for Pherin Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Pherin Pharmaceuticals
3 dated milestones of Pherin Pharmaceuticals across 31 years, from founding to its latest funding, stage changes and deals.
- Founded Pherin Pharmaceuticals is founded.
- Funding First funding round of $1.5M.
- Exit Acquired by VistaGen.
Competitors of Pherin Pharmaceuticals
Pherin Pharmaceuticals has 3 listed competitors in our database, 2 of them funded. They include Alto Neuroscience, Supernus Pharmaceuticals and Neurovance.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| altoneuroscience.com | 2019 | San Francisco, United States | $144.72M | 34 | AI-driven drug discovery platform for neurological diseases based on patients biomarkers | |
| supernus.com | 2005 | Rockville, United States | 652 | Specialty pharmaceutical products for CNS diseases are developed and commercialized. | ||
| neurovance.com | 2011 | Cambridge, United States | $53.03M | 7 | Neurochemical modulators for ADHD treatment are developed by Neurovance. |
Detailed competitors of Pherin Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Pherin Pharmaceuticals
Websites that share an audience with Pherin Pharmaceuticals (pherin.com).
Websites whose visitors overlap most with Pherin Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| thresholdpharm.com | 100% | View details | |||
| sucampo.com | 98% | View details | |||
| aqxpharma.com | 98% | 3K | #6,768,702 | View details | |
| noven.com | 98% | 7.2K | #3,107,578 | View details | |
| pacira.com | 98% | 39.1K | #1,306,031 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 8 similar websites and full traffic analytics for Pherin Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Pherin Pharmaceuticals (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pherin Pharmaceuticals
Complete news archive for Pherin Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pherin Pharmaceuticals
Pherin Pharmaceuticals was founded in 1991 and raised its 1st funding round 8 years after it was founded.
Pherin Pharmaceuticals is headquartered in Los Altos, United States. It is registered at Los Altos, California, United States.
Kevin McCarthy is the CEO of Pherin Pharmaceuticals, as recorded in our data.
Pherin Pharmaceuticals is a clinical stage specialty drug development company. It develops intranasal spray delivery in ultra low (nanogram) dose. It works exclusively with a set of proprietary compounds called pherines for the acute and PRN treatment of neuropsychiatric and neuroendocrine conditions. Pherines act by binding to nasal receptors and initiating neural impulses that are transmitted by specific neural circuits that directly and rapidly affect brain function. Their pipeline consists of four lead compounds: Aloradine IN for acute treatment of Social Anxiety Disorder (currently in Phase III); PH10 nasal spray for acute treatment of Depression (currently in Phase II); Salubrin HF NS, for acute management of Menopausal Hot Flashes and other symptoms of menopause (also in Phase II); and PH15 nasal spray for Cognitive Improvement (in Phase I trials).
Pherin Pharmaceuticals's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Neurovance.
Pherin Pharmaceuticals has 2 investors. Key investors include VistaGen, and Johnson & Johnson Innovation β JJDC.
Yes. Pherin Pharmaceuticals was acquired by VistaGen in December 2022.

